Phase 1 CARDINAL trial evaluating TERN-701 in 2L+ CML patients remains ongoing, with interim data from initial cohorts anticipated in second half of 2024 FOSTER CITY, Calif., April 29, 2024 (GLOBE ...
SUZHOU, China, and ROCKVILLE, MD, Jan. 18, 2023 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B ...
Enliven Therapeutics jumped on strong ELVN-001 phase 1b CML data, but a rich valuation may cap upside. Click here to read an ...
Expert Rev Anticancer Ther. 2008;8(9):1387-1398. Expert Rev Anticancer Ther. 2008;8(9):1387-1398. © 2008 Expert Reviews Ltd. No writing assistance was utilized in ...
Ability to dose TERN-701 without regard to food represents a key potential differentiator within the allosteric BCR-ABL inhibitor class Pharmacokinetic data show no clinically significant difference ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback